4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

S-3ASR - BioAge Labs, Inc. (0001709941) (Filer)

S-8 - BioAge Labs, Inc. (0001709941) (Filer)

10-K - BioAge Labs, Inc. (0001709941) (Filer)

8-K - BioAge Labs, Inc. (0001709941) (Filer)

144 - BioAge Labs, Inc. (0001709941) (Subject)

SCHEDULE 13G/A - BioAge Labs, Inc. (0001709941) (Subject)

144 - BioAge Labs, Inc. (0001709941) (Subject)

8-K - BioAge Labs, Inc. (0001709941) (Filer)

424B5 - BioAge Labs, Inc. (0001709941) (Filer)

424B5 - BioAge Labs, Inc. (0001709941) (Filer)

Oppenheimer initiated coverage of BioAge Labs with a rating of Outperform and set a new price target of $60.00

Jefferies upgraded BioAge Labs from Hold to Buy and set a new price target of $62.00

Piper Sandler initiated coverage of BioAge Labs with a rating of Overweight and set a new price target of $73.00

Morgan Stanley upgraded BioAge Labs from Underweight to Equal-Weight and set a new price target of $12.00

Citigroup upgraded BioAge Labs from Neutral to Buy and set a new price target of $10.00

William Blair initiated coverage of BioAge Labs with a rating of Mkt Perform

Morgan Stanley downgraded BioAge Labs from Overweight to Underweight and set a new price target of $5.00 from $40.00 previously

Jefferies downgraded BioAge Labs from Buy to Hold and set a new price target of $7.00 from $42.00 previously

Citigroup downgraded BioAge Labs from Buy to Neutral and set a new price target of $7.00 from $45.00 previously

Citigroup initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $45.00

4/A - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory biomarkers of cardiovascular risk; Phase 2a proof-of-concept trial planned to initiate in 1H 2026 Indication expansion for BGE-102 into ophthalmology; Phase 1b/2a proof-of-concept trial in diabetic macular edema planned to initiate mid-2026 Completed upsized follow-on public offering of $132.3 million with full exercise of the underwriters' overallotment option in February 2026 EMERYVILLE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a cl

STOCKHOLM, March 23, 2026 /PRNewswire/ -- BioArctic's AB (publ) (NASDAQ:BIOA) partner Eisai presented new data at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™), held in Copenhagen, Denmark March 17-21. BioArctic also held an oral presentation on lecanemab and a poster presentation relating to exidavnemab.   Eisai presented new real-world findings from an analysis of long-term treatment persistence among early Alzheimer's disease patients in the United States receiving intravenous (IV) lecanemab. Based on data from the PurpleLab®[1] claims database, the analysis showed that most patients continued lecanemab therapy after

EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place February 25-26, 2026. Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, February 26 from 10:40 AM to 11:05 AM ET. Fortney and Dov Goldstein, MD, CFO, will participate in one-on-one meetings. To access the live webcast of the presentation, register here. Replay

EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. The gross proceeds from this offering are expected to be approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by BioAge. The offering is expected to close on or about January 23, 2026, subject to the satisfact

EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75.0 million of shares of its common stock. In addition, BioAge intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares of common stock are being offered by BioAge. The proposed offering is subject to mar

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and clinical evidence points to central role of the inflammasome in multiple retinal diseases where inflammation is a key feature, including diabetic macular edema (DME) BGE-102 has demonstrated favorable tolerability to date in ongoing Phase 1 trial, with robust reductions in key inflammatory biomarkers including hsCRP, IL-6, and IL-1β Proof-of-concept trial in DME is designed to demonstrate ocular target engagement, supporting future development across inflammation-driven retinal diseases DME tri

First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels (<2 mg/L) BGE-102 demonstrated significant reductions in IL-6, a key driver of systemic inflammation and cardiovascular risk, and fibrinogen, an independent predictor of cardiovascular events BGE-102 was well tolerated with a favorable safety profile Patent issued covering additional composition of matter and novel NLRP3 binding site Full Phase 1 data, including additional MAD cohorts in obese participants with elevated hsCR

BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a cytokine directly downstream of NLRP3, at Day 14 High brain penetration: BGE-102 doses of 60 mg and higher exceeded target IC90 levels in cerebrospinal fluid (CSF) at Day 14 Company is expanding the Phase 1 trial to include MAD cohorts in participants with obesity and elevated hsCRP, with data anticipated in first half of 2026 EMERYVILLE, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic pro

EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference taking place in New York, NY on December 2-4, 2025. Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Thursday, December 4 from 1:30 - 1:55 PM ET, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here. Replays of

EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Jefferies Global Healthcare Conference in London, November 17–20, 2025. Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Monday, November 17 from 7:30 - 7:55 AM ET (12:30 - 1 PM GMT), and will participate in one-on-one meetings. To access the live webcast of the presentation, register here. Replays of the webcas

SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

SC 13D - BioAge Labs, Inc. (0001709941) (Subject)

SC 13D - BioAge Labs, Inc. (0001709941) (Subject)